Alx Oncology Holdings INC Form 4 insider transactions

Shelly Wong, SVP, Finance and CAO of ALX Oncology Holdings Inc., reported a sale of 1,404 common shares on July 1, 2026, to cover tax obligations related to vesting restricted stock units.

Chief Development and Operating Officer Jeff E. Knight was granted 800,000 stock options in ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc. Chief Medical Officer Barbara Klencke was granted 100,000 stock options on April 16, 2026.

ALX Oncology Holdings Inc. CEO Jason Lettmann sold 12,311 shares of common stock to cover tax obligations from vested restricted stock units.

ALX Oncology Holdings Inc.'s SVP of Finance and CAO, Shelly Pinto, sold 903 shares of common stock to cover tax obligations related to vested restricted stock units.

ALX Oncology Holdings Inc.'s Chief Medical Officer, Barbara Klencke, was granted 700,000 stock options with an exercise price of $2.07 per share.

ALX Oncology Holdings Inc. CEO Jason Lettmann disposed of 2,201 shares of common stock to cover tax liabilities related to RSU vesting.

Corey S. Goodman, a Director and 10% owner of ALX Oncology Holdings Inc., acquired over 3.18 million shares of common stock through a pre-planned transaction.

ALX Oncology Holdings Inc.'s Chief Financial Officer, Harish Shantharam, was granted 303,000 stock options with an exercise price of $1.48.

ALX Oncology Holdings Inc. SVP of Finance and CAO, Shelly Pinto, was granted 192,000 stock options at an exercise price of $1.48.

ALX Oncology Holdings Inc. CEO Jason Lettmann was granted 912,000 stock options with an exercise price of $1.48, vesting over 48 months.

ALX Oncology Holdings Inc. Director Alan B. Sandler was granted 10,100 stock options with an exercise price of $1.32, vesting monthly starting February 20, 2026.

ALX Oncology Holdings Inc. Director Daniel J. Curran was granted 16,833 stock options with an exercise price of $1.32, vesting monthly starting February 20, 2026.

ALX Oncology Holdings Inc. Director Chris H. Takimoto was granted 40,400 stock options with an exercise price of $1.32, vesting over 12 months.

ALX Oncology Holdings Inc. Director Rekha Hemrajani reported the acquisition of 40,400 stock options with an exercise price of $1.32, vesting monthly starting February 20, 2026.

ALX Oncology Holdings Inc. Director and 10% Owner Corey S. Goodman was granted 40,400 stock options with an exercise price of $1.32, vesting monthly starting February 20, 2026.

ALX Oncology Holdings Inc. Director J. Scott Garland was granted 40,400 stock options with an exercise price of $1.32, vesting monthly starting February 20, 2026.

ALX Oncology's SVP of Finance and CAO, Shelly Pinto, sold 3,925 shares of common stock to cover tax obligations related to restricted stock unit vesting.

ALX Oncology Holdings Inc. SVP of Finance and CAO, Shelly Pinto, was granted 140,000 employee stock options with an exercise price of $1.7.

ALX Oncology Holdings Inc. CEO Jason Lettmann acquired 597,500 employee stock options with an exercise price of $1.70.

ALX Oncology Holdings Inc.'s Chief Financial Officer, Harish Shantharam, was granted 198,750 employee stock options with an exercise price of $1.7.

ALX Oncology Holdings Inc. Director Barbara Klencke was granted 300,000 stock options with an exercise price of $1.05, vesting over three dates.

ALX Oncology Holdings Inc. CEO Jason Lettmann acquired 92,233 shares of common stock in open market purchases on September 16 and 17, 2025, increasing his direct beneficial ownership.

ALX Oncology Holdings Inc.'s Chief Financial Officer, Harish Shantharam, acquired 75,000 shares of common stock.

ALX Oncology's SVP of Finance and CAO, Shelly Pinto, sold 611 shares of common stock to cover tax obligations related to restricted stock unit vesting.

ALX Oncology Holdings Inc. CEO Jason Lettmann sold 2,382 shares of common stock at a weighted average price of $0.6404 to cover tax obligations related to restricted stock unit vesting.

ALX Oncology Holdings Inc. Director Daniel J. Curran was granted 40,400 stock options with a $0.615 exercise price, vesting monthly over three years.

Shelly Pinto, SVP of Finance and CAO at ALX Oncology Holdings Inc., sold 2,011 shares of common stock on July 7, 2025, at a weighted average price of $0.4501 to satisfy tax obligations related to restricted stock unit vesting.

Shelly Pinto, SVP of Finance and CAO at ALX Oncology Holdings Inc., sold 1,532 shares of common stock to cover tax obligations related to restricted stock unit vesting, executed under a Rule 10b5-1 plan.

Shelly Pinto, SVP of Finance and CAO at ALX Oncology Holdings Inc., acquired 90,000 employee stock options on April 11, 2025, according to a recent SEC filing.